Drug Profile
Research programme: androgen receptor antagonists - Astellas Pharma
Alternative Names: Androgen receptor antagonists research programme - Astellas Pharma; N-arylpiperazine 1-carboxamides - Astellas Pharma; YM 580; YM 92088Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Amides; Small molecules
- Mechanism of Action Testosterone congener inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in Japan
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 31 Mar 2005 Preclinical trials in Prostate cancer in Japan (unspecified route)